Which has preferable earnings & valuation, OGN or ARDX?

Organon & Co. has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organon & Co. $6.13B 0.58 $187M $0.77 17.72 Ardelyx $407.32M 2.19 -$61.60M -$0.22 N/A

Is OGN or ARDX more profitable?

Organon & Co. has a net margin of 3.41% compared to Ardelyx's net margin of -12.35%. Organon & Co.'s return on equity of 88.97% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Organon & Co. 3.41% 88.97% 6.03% Ardelyx -12.35% -36.00% -10.77%

Does the media favor OGN or ARDX?

In the previous week, Organon & Co. had 6 more articles in the media than Ardelyx. MarketBeat recorded 9 mentions for Organon & Co. and 3 mentions for Ardelyx. Organon & Co.'s average media sentiment score of 1.24 beat Ardelyx's score of 0.88 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RGC or ARDX?

Ardelyx has a consensus price target of $13.90, suggesting a potential upside of 288.27%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ardelyx 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable valuation & earnings, RGC or ARDX?

Regencell Bioscience has higher earnings, but lower revenue than Ardelyx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Ardelyx $407.32M 2.19 -$61.60M -$0.22 N/A

Does the media refer more to GPCR or ARDX?

In the previous week, Structure Therapeutics had 14 more articles in the media than Ardelyx. MarketBeat recorded 17 mentions for Structure Therapeutics and 3 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.88 beat Structure Therapeutics' score of 0.68 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARQT or ARDX?

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Ardelyx. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 3 mentions for Ardelyx. Arcutis Biotherapeutics' average media sentiment score of 1.04 beat Ardelyx's score of 0.88 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARDX or MBX more profitable?

MBX Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. MBX Biosciences' return on equity of -26.02% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -12.35% -36.00% -10.77% MBX Biosciences N/A -26.02% -24.94%

Does the media prefer ARDX or MBX?

In the previous week, MBX Biosciences had 1 more articles in the media than Ardelyx. MarketBeat recorded 4 mentions for MBX Biosciences and 3 mentions for Ardelyx. MBX Biosciences' average media sentiment score of 1.09 beat Ardelyx's score of 0.88 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ardelyx (ARDX) Competitors

$3.58 -0.04 (-1.10%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.60 +0.02 (+0.59%)

As of 09/11/2026 07:56 PM Eastern

Compare

ARDX vs. OGN, RGC, GPCR, ARQT, and MBX

Should you buy Ardelyx stock or one of its competitors? Ardelyx's main competitors and comparable companies include Organon & Co. (OGN), Regencell Bioscience (RGC), Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), and MBX Biosciences (MBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ardelyx compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Organon & Co. currently has a consensus target price of $11.40, suggesting a potential downside of 16.45%. Ardelyx has a consensus target price of $13.90, suggesting a potential upside of 288.27%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Organon & Co. has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.13B	0.58	$187M	$0.77	17.72
Ardelyx	$407.32M	2.19	-$61.60M	-$0.22	N/A

In the previous week, Organon & Co. had 6 more articles in the media than Ardelyx. MarketBeat recorded 9 mentions for Organon & Co. and 3 mentions for Ardelyx. Organon & Co.'s average media sentiment score of 1.24 beat Ardelyx's score of 0.88 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a net margin of 3.41% compared to Ardelyx's net margin of -12.35%. Organon & Co.'s return on equity of 88.97% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Ardelyx	-12.35%	-36.00%	-10.77%

Organon & Co. has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Summary

Organon & Co. beats Ardelyx on 11 of the 17 factors compared between the two stocks.

How does Ardelyx compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Regencell Bioscience has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Regencell Bioscience has higher earnings, but lower revenue than Ardelyx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Ardelyx	$407.32M	2.19	-$61.60M	-$0.22	N/A

In the previous week, Ardelyx had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 3 mentions for Ardelyx and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.87 beat Ardelyx's score of 0.88 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Very Positive
Ardelyx	Positive

Regencell Bioscience has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Regencell Bioscience's return on equity of 0.00% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Ardelyx	-12.35%	-36.00%	-10.77%

Ardelyx has a consensus price target of $13.90, suggesting a potential upside of 288.27%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Ardelyx beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Ardelyx compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Structure Therapeutics had 14 more articles in the media than Ardelyx. MarketBeat recorded 17 mentions for Structure Therapeutics and 3 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.88 beat Structure Therapeutics' score of 0.68 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Ardelyx	$407.32M	2.19	-$61.60M	-$0.22	N/A

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Structure Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Structure Therapeutics' return on equity of -25.56% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Ardelyx	-12.35%	-36.00%	-10.77%

Structure Therapeutics has a beta of -1.45, indicating that its stock price is 245% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Structure Therapeutics currently has a consensus target price of $110.91, indicating a potential upside of 186.88%. Ardelyx has a consensus target price of $13.90, indicating a potential upside of 288.27%. Given Ardelyx's higher probable upside, analysts clearly believe Ardelyx is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Structure Therapeutics and Ardelyx tied by winning 8 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

58.9% of Ardelyx shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arcutis Biotherapeutics presently has a consensus target price of $35.57, indicating a potential upside of 48.90%. Ardelyx has a consensus target price of $13.90, indicating a potential upside of 288.27%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Arcutis Biotherapeutics has a net margin of 6.15% compared to Ardelyx's net margin of -12.35%. Arcutis Biotherapeutics' return on equity of 15.05% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Ardelyx	-12.35%	-36.00%	-10.77%

Arcutis Biotherapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Ardelyx. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 3 mentions for Ardelyx. Arcutis Biotherapeutics' average media sentiment score of 1.04 beat Ardelyx's score of 0.88 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$463.98M	6.47	-$16.14M	$0.21	113.76
Ardelyx	$407.32M	2.19	-$61.60M	-$0.22	N/A

Summary

Arcutis Biotherapeutics beats Ardelyx on 12 of the 17 factors compared between the two stocks.

How does Ardelyx compare to MBX Biosciences?

Ardelyx (NASDAQ:ARDX) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Ardelyx has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

In the previous week, MBX Biosciences had 1 more articles in the media than Ardelyx. MarketBeat recorded 4 mentions for MBX Biosciences and 3 mentions for Ardelyx. MBX Biosciences' average media sentiment score of 1.09 beat Ardelyx's score of 0.88 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. MBX Biosciences' return on equity of -26.02% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
MBX Biosciences	N/A	-26.02%	-24.94%

58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Comparatively, 31.1% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ardelyx currently has a consensus target price of $13.90, suggesting a potential upside of 288.27%. MBX Biosciences has a consensus target price of $77.00, suggesting a potential upside of 30.46%. Given Ardelyx's higher possible upside, equities research analysts plainly believe Ardelyx is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Ardelyx has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	2.19	-$61.60M	-$0.22	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Summary

Ardelyx beats MBX Biosciences on 8 of the 15 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDX vs. The Competition

Export

Metric	Ardelyx	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$902.06M	$12.43B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-16.27	799.75	275.24	25.29
Price / Sales	2.19	763.36	656.02	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	5.19	10.39	10.33	6.20
Net Income	-$61.60M	$2.85B	$3.50B	$358.50M
7 Day Performance	-5.29%	-3.61%	-3.32%	-2.35%
1 Month Performance	-9.82%	0.86%	-0.41%	-2.77%
1 Year Performance	-45.84%	3.47%	19.21%	7.63%

Ardelyx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDX Ardelyx	2.9378 of 5 stars	$3.58 -1.1%	$13.90 +288.3%	-46.4%	$902.06M	$407.32M	N/A	90
OGN Organon & Co.	1.5878 of 5 stars	$13.78 flat	$11.40 -17.3%	+28.0%	$3.62B	$6.22B	17.90	10,000
RGC Regencell Bioscience	0.4766 of 5 stars	$6.89 flat	N/A	-58.1%	$3.41B	N/A	N/A	10	Positive News Gap Up High Trading Volume
GPCR Structure Therapeutics	2.6522 of 5 stars	$47.34 flat	$110.91 +134.3%	+85.2%	$3.30B	N/A	N/A	136	Positive News Analyst Forecast
ARQT Arcutis Biotherapeutics	3.8752 of 5 stars	$23.90 flat	$35.57 +48.8%	+35.0%	$3.00B	$376.07M	113.81	150	Positive News Analyst Downgrade Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardelyx (ARDX) Competitors

ARDX vs. OGN, RGC, GPCR, ARQT, and MBX

How does Ardelyx compare to Organon & Co.?

Summary

How does Ardelyx compare to Regencell Bioscience?

Summary

How does Ardelyx compare to Structure Therapeutics?

Summary

How does Ardelyx compare to Arcutis Biotherapeutics?

Summary

How does Ardelyx compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardelyx (ARDX) Competitors

ARDX vs. OGN, RGC, GPCR, ARQT, and MBX

How does Ardelyx compare to Organon & Co.?

Do institutionals and insiders hold more shares of OGN or ARDX?

Do analysts recommend OGN or ARDX?

Which has preferable earnings & valuation, OGN or ARDX?

Does the media favor OGN or ARDX?

Is OGN or ARDX more profitable?

Which has more risk & volatility, OGN or ARDX?

Summary

How does Ardelyx compare to Regencell Bioscience?

Which has more volatility & risk, RGC or ARDX?

Do insiders & institutionals hold more shares of RGC or ARDX?

Which has preferable valuation & earnings, RGC or ARDX?

Does the media refer more to RGC or ARDX?

Is RGC or ARDX more profitable?

Do analysts rate RGC or ARDX?

Summary

How does Ardelyx compare to Structure Therapeutics?

Does the media refer more to GPCR or ARDX?

Which has stronger valuation & earnings, GPCR or ARDX?

Do institutionals and insiders have more ownership in GPCR or ARDX?

Is GPCR or ARDX more profitable?

Which has more volatility and risk, GPCR or ARDX?

Do analysts recommend GPCR or ARDX?

Summary

How does Ardelyx compare to Arcutis Biotherapeutics?

Do institutionals and insiders believe in ARQT or ARDX?

Do analysts recommend ARQT or ARDX?

Is ARQT or ARDX more profitable?

Which has more risk and volatility, ARQT or ARDX?

Does the media favor ARQT or ARDX?

Which has better valuation and earnings, ARQT or ARDX?

Summary

How does Ardelyx compare to MBX Biosciences?

Which has more volatility and risk, ARDX or MBX?

Does the media prefer ARDX or MBX?

Is ARDX or MBX more profitable?

Do insiders & institutionals hold more shares of ARDX or MBX?

Do analysts rate ARDX or MBX?

Which has stronger earnings & valuation, ARDX or MBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools